Discovery News
Sun Pharma arm opts for rights issue to conduct clinical trials in US
In the first initiative of its kind, Sun Pharma Advanced Research Company (SPARC) will issue additional shares to its existing shareholders to raise funds to conduct clinical trials in the world’s biggest pharma market, the US.
SPARC, a publicly-listed company, is a hived-off entity of drug maker Sun Pharmaceuticals.
The proceeds from the Rs 200-cr rights issue will go towards safety and efficacy
Discovery Galleries
Discovery Videos
|
|
